Abstract: Systems, apparatuses, and methods disclosed herein may be directed to clips for medical implementation, including clips for a portion of a heart. The clips may be configured to close the portion of the heart, to reduce blood flow therethrough as well as passage of clots or other undesired materials. In examples, the clips may be configured to close the left atrial appendage (LAA). The closure of the LAA may reduce the possibility of stroke or other maladies stemming from fluid flow with the LAA. In examples, the clips may be positioned exterior of the LAA, to extend over an outer surface of the LAA for closure.

Abstract: Presented are embedded control systems with logic for computation and data sharing, methods for making/using such systems, and vehicles with distributed sensors and embedded processing hardware for provisioning automated driving functionality. A method for operating embedded controllers connected with distributed sensors includes receiving a first data stream from a first sensor via a first embedded controller, and storing the first data stream with a first timestamp and data lifespan via a shared data buffer in a memory device. A second data stream is received from a second sensor via a second embedded controller. A timing impact of the second data stream is calculated based on the corresponding timestamp and data lifespan. Upon determining that the timing impact does not violate a timing constraint, the first data stream is purged from memory and the second data stream is stored with a second timestamp and data lifespan in the memory device.

Abstract: Disclosed are assays, protocols and reagents to facilitate clinical management of pregnancy with improved pre- and post-natal health outcomes for fetuses developing in an environment of placental insufficiency.

Abstract: A therapeutic protocol to induce placenta cell death when required in the treatment of an adverse gynecological condition is applicable, inter alia, to the treatment of ectopic pregnancy, including unruptured ectopic pregnancy and placenta tumors, such as a hydatidiform molar pregnancy or choriocarcinoma.

Abstract: The invention pertains to methods for treating ectopic pregnancy. More particularly, the present invention relates to methods for treating unruptured ectopic pregnancy using a non-surgical method comprising the administration of an EGFR inhibitor alone or in combination with an anti-metabolite e.g. methotrexate (MTX). The methodology is potentially applicable to treatment of unruptured ectopic pregnancies of all sizes.

Abstract: The present invention relates to a double-stranded siRNA molecule that is capable of silencing gene expression as well as inducing an immune response. The molecule comprises a sense strand and an antisense strand, wherein the antisense strand comprises a first nucleotide sequence that is specifically complementary to mRNA transcribed from a target gene, and the sense strand comprises a second nucleotide sequence that is substantially or perfectly complementary to the antisense strand with the exception that the second nucleotide sequence comprises at least one immunostimulatory motif comprising two or more non-complementary nucleotides. Such a molecule may be utilized in a method of treating or preventing a disease or condition (such as a viral infection, a bacterial infection, or cancer) in a subject.

Abstract: The invention pertains to methods for treating ectopic pregnancy. More particularly, the present invention relates to methods for treating unruptured ectopic pregnancy using a non-surgical method comprising the administration of an EGFR inhibitor alone or in combination with an anti-metabolite e.g. methotrexate (MTX). The methodology is potentially applicable to treatment of unruptured ectopic pregnancies of all sizes.

Abstract: The present invention relates to a double-stranded siRNA molecule that is capable of silencing gene expression as well as inducing an immune response. The molecule comprises a sense strand and an antisense strand, wherein the antisense strand comprises a first nucleotide sequence that is specifically complementary to mRNA transcribed from a target gene, and the sense strand comprises a second nucleotide sequence that is substantially or perfectly complementary to the antisense strand with the exception that the second nucleotide sequence comprises at least one immunostimulatory motif comprising two or more non-complementary nucleotides. Such a molecule may be utilized in a method of treating or preventing a disease or condition (such as a viral infection, a bacterial infection, or cancer) in a subject.